Long Term Study With B2036-PEG

NCTNCT00143416Other idA6291011

Open at ClinicalTrials.govAsk about this trial

Overview

Status: Completed
Phase: Phase 3
Enrollment: 16 participants
Sponsor: Pfizer · Industry
Design: Not randomized · Open label (no masking)
Countries: 1 country
Japan
Start: Apr 2004
Primary completion: Not stated
Completion: Jul 2007
First posted: 2 Sept 2005 (estimated)
Last update posted: 29 Jul 2008 (estimated)
Conditions: Acromegaly

Timeline

1 trial · 1 completed

Completed
Ongoing
Not yet recruiting
Stopped
Estimated dates (est.)
Results posted

20042005200620072008

Ph 3
Long Term Study With B2036-PEG
NCT00143416
Apr 2004 to Jul 2007

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

Primary objective: To investigate the efficacy and safety of Pegvisomant in Japanese patients with acromegaly.

Interventions

PegvisomantDrug

Arms0

The registry lists no arms for this trial.

Primary outcomes1

Outcomes the sponsor listed as primary.

To evaluate the safety and efficacy of long-term B2036-PEG therapy in patients with acromegaly

Secondary outcomes(1)

PK/PD evaluation

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

Completed trials do not always post results.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies0

Studies that cite this trial.

No study cites this trial.

Eligibility

Who could join, as posted.

Sex: All
Age: from 20 Years up to 75 Years
Healthy volunteers: Not accepted

Inclusion and exclusion criteria, as posted

Inclusion Criteria: * Patients with acromegaly who have received at least one dose of B2036-PEG in the preceding study (A6291009). Exclusion Criteria: * Switching to other therapeutic methods for acromegaly

PepBank is a research reference. Talk to a doctor before you use any peptide.